Solanezumab does not slow cognitive decline in patients with

1. In this randomized controlled trial, over a period of 240 weeks, solanezumab did not slow cognitive decline as compared to placebo in patients with preclinical Alzheimer’s disease. 2. Solanezumab did not change the levels of amyloid levels in the brain as compared to placebo in persons with preclinical Alzheimer’s disease. Evidence Rating Level: 1 (Excellent)

Related Keywords

, Minute Medicine Inc , Rating Level , Mild Dementia Due , Clinical Dementia Rating , Mental State Examination , Preclinical Alzheimer , Cognitive Composite , Alzheimer 039 S , Alzheimers Disease , Amyloid , Chronic Disease , Neurology , Solanezumab ,